About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

UNKNOWNPhase 2

Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma

Chidamide Combined With Cladribine/Gemcitabine/Busulfan (ChiCGB) With Autologous Stem-Cell Transplantation in Relapsed and Refractory Diffuse Large B Cell Lymphoma

NCT03151876•Sichuan University

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Lymphoma

Interventions

Chidamide

Cladribine

+3 more

Locations

18

China

Locations (18)

Beijing cancer hospital

Beijing, Beijing Municipality, China

Peking university third hospital

Beijing, Beijing Municipality, China

The first affiliated hospital of Chongqing medical university

Chongqing, Chongqing Municipality, China

Southwest Hospital

Chongqing, Chongqing Municipality, China

General Hospital of Lanzhou military command

Lanzhou, Gansu, China

Henan cancer hospital

Zhengzhou, Henan, China

Key Dates

Start Date

June 12, 2017

Primary Completion Date

December 1, 2020

Completion Date

December 1, 2021

Last Updated

July 18, 2018

Related Studies

RECRUITINGPhase 2/3

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

DLBCLDiffuse Large B-Cell Lymphoma

RECRUITINGPhase 2

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

NCT05529069

Mantle Cell LymphomaNon Hodgkin Lymphoma+1 more

RECRUITINGPhase 3

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

NCT06337318

Classic Follicular LymphomaFollicular Lymphoma With Unusual Cytological Features

RECRUITINGPhase 1

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

NCT07388563

Lymphoma, T Cell, PeripheralT-cell Lymphoma+4 more

RECRUITINGPhase 2

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

NCT06263491

Mantle Cell Lymphoma

RECRUITINGPhase 1

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

NCT06189391

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

View all related studies

Contacts

Jie Ji, MD

CONTACT

86-28-85422370 JieJi@scu.edu.cn

Ting Liu, MD

CONTACT

86-28-85422373 liuting@scu.edu.cn

Sponsors

Lead Sponsor

Sichuan University

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 18, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions